Reply to Singh et al.

Hechtman, Jaclyn F.; Soslow, Robert A.; Shia, Jinru

doi:10.1038/s41379-021-00784-z

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 13% of ampullary cancers exhibit HER2 amplification, which does not appear to affect prognosis [29,30]. Very limited data exist on treatment of HER2-amplified ampullary cancer (Table 1).…”

Section: Molecular Tumor Boardmentioning

confidence: 99%

Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature

et al. 2021

View full text Add to dashboard Cite

HER2 amplification, which results in overexpression of the receptor tyrosine kinase HER2, has been described in a wide variety of malignancies. HER2-targeting agents have been incorporated into the treatment paradigms for HER2overexpressing breast and gastric cancer. More recently, these agents have shown promise in other gastrointestinal malignancies, such as colon cancer and biliary tract tumors. Herein we discuss two patients with gallbladder carcinoma (GBC) and a third with ampullary carcinoma who were able to achieve marked responses to HER2-directed therapy. These cases underscore the importance of molecular analysis for HER2 amplification/HER2 overexpression, irrespective of tumor histology, and highlight a need for further investigation of HER2-directed therapy beyond breast and gastroesophageal cancers. The Oncologist 2021;9999:• • KEY POINTS• Current guidelines recommend molecular assessment for HER2-oversexpression exclusively in breast and gastric adenocarcinoma • The focus of this report is on three cases (two biliary tract and one ampullary carcinoma) in which amplification of HER2 or overexpression of HER2 is detected and treatment with HER2-directed therapy resulted in robust responses • These cases exemplify responsiveness of non-breast/gastric histologies to HER2-directed therapies, highlighting several promising new settings for these agents • Testing for amplification of HER2 or overexpression of HER2 should be considered especially in rare diseases with limited treatment options

show abstract

Section: Molecular Tumor Boardmentioning

confidence: 99%